Physician profile
Jonathan J Gries
NPI 1801116819
$2,470.65
in general payments reported to CMS, 2019-2025
26 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2023: $259 · 2024: $905 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,247 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,246.69 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $399.80 | 2019-2025 | |
| Glaxosmithkline, LLC. | $221.03 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $215.39 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $207.46 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.31 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $174.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $135.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $117.97 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $101.89 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $88.29 | 2023-2025 | Injectafer |
| Amgen INC. | $75.85 | 2023-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $73.88 | 2024-2025 | Veozah |
| Medtronic, INC. | $72.04 | 2023-2025 | Intellis Adaptivestim, Inceptiv, Venaseal |
| Inspire Medical Systems, INC. | $51.39 | 2024-2025 | Inspire |
| Merck Sharp & Dohme LLC | $49.79 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $48.83 | 2024-2025 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $47.44 | 2024-2025 | Heplisav-B |
| Axsome Therapeutics, INC. | $37.88 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.97 | 2024-2025 | Xifaxan |
| Nevro Corp. | $27.67 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.29 | 2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $19.61 | 2025 | |
| Idorsia Pharmaceuticals US INC | $17.35 | 2023 | Quviviq |
| Antares Pharma, INC. | $16.09 | 2025 | Xyosted |
| Eisai INC. | $11.90 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Gries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.